P
Panacea Biotec
Panacea Biotec GmbH is delivers and markets products in transplantation, immunsuppression and anti-infection
About Panacea Biotec
Panacea Biotec is a research-driven biotechnology company engaged in the research, development, manufacturing, and marketing of pharmaceuticals and vaccines. Founded in 1984 by Soshil Kumar Jain as Panacea Drugs Private Limited, the company was established with the goal of making specialized products affordable and accessible. Soshil Kumar Jain, a qualified pharmacist, began his career in the pharmaceutical industry in a chemist shop started by his father and had 56 years of experience in the sector. The company went public and was listed on Indian stock exchanges in September 1995, at which point its name was changed to Panacea Biotec Ltd.
The company's business model encompasses the entire value chain from research and development to sales and distribution. Revenue is primarily generated from two main segments: vaccines and pharmaceutical formulations, with the majority coming from the vaccines division. A significant portion of its revenue is derived from overseas markets. The company supplies its products to institutional customers such as UNICEF and PAHO, as well as marketing them in approximately 30 countries across the CIS, Latin America, the Middle East, Asia, and Africa. It operates state-of-the-art manufacturing facilities in locations like Baddi and Lalru, which are accredited by international bodies including the USFDA and WHO.
Panacea Biotec's product portfolio is extensive, covering therapeutic areas such as oncology, nephrology (organ transplantation), pain management, diabetes, and gastroenterology. A key achievement was the 2011 launch of PacliAll, the first generic version of the cancer drug Abraxane, which utilizes nanotechnology. The company holds a prominent position in the vaccine market, being a major manufacturer in India. It has been a significant partner in the Global Polio Eradication Initiative, supplying billions of doses of WHO pre-qualified polio vaccines globally. Notable products include EasyFive, the first fully-liquid pentavalent vaccine developed in 2005, and EasySix, the first fully-liquid hexavalent vaccine launched in 2017. The company has also been involved in developing vaccines for other diseases, including a collaboration with the Russian Direct Investment Fund to produce the Sputnik V COVID-19 vaccine.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Sep 2024 | $20M | — | U.S. International Development Finance Corporation | ↗ |
| SECONDARYOther financing | May 2021 | $16M | — | Serum Institute of India | — |
Growth signals
Latest recorded traffic for Panacea Biotec is 19K monthly website visits, up 5.6% over the last three months. Panacea Biotec's team grew 0.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Panacea Biotec in the Lalru ecosystem
The Panacea Biotec office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Serum Institute of India
U.S. International Development Finance Corporation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Panacea Biotec on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Panacea Biotec’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







